Alcon
ALC Healthcare Medical Instruments & Supplies
Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024.
- Revenue
- +8.74%
- EPS
- −100.0%
- Free cash flow
- −0.54%
- Total debt
- −0.55%
Quarter to June 2026, against a year earlier
Follow ALC
Alert me
Alcon (ALC) P/E ratio
As of 5 November 2026, Alcon (ALC) trades at a P/E ratio of 58.4×. Over the past ten years it has ranged from 0.0× (June 2021) to 236× (September 2021); the current reading is higher than 72% of that period. That is above the Medical Instruments & Supplies industry median of 30.3× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 39.6× | (4.36%) |
| FY2024 | 41.4× | 5.89% |
| FY2023 | 39.1× | (61.45%) |
| FY2022 | 101× | (11.03%) |
| FY2021 | 114× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 21.7× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 51.2× | 13.52% |
| Mar 2026 | 45.1× | 13.93% |
| Dec 2025 | 39.6× | 12.68% |
| Sep 2025 | 35.1× | (13.61%) |
| 28 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BAX Baxter International Inc. compare | n/m |
| COO The Cooper Companies, Inc. compare | 21.7× |
| RMD ResMed Inc. compare | 21.7× |
| ALGN Align Technology, Inc. compare | 23.1× |
| WST West Pharmaceutical Services, Inc. compare | 43.8× |
| ALC Alcon | 58.4× |
| MDLN Medline Inc. compare | 58.4× |
| BDX Becton, Dickinson and Company compare | 64.1× |
| SOLV Solventum Corporation compare | 97.3× |
| Medical Instruments & Supplies industry median | 30.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on ALC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement